RedHill Biopharma develops medicines for gastrointestinal and infectious diseases, promoting drugs like Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage programs include RHB-204, opaganib, RHB-107, RHB-104, and RHB-102.
RDHL has been in the news recently: GC Biopharma USA presented new data at the 2025 ISTH Congress indicating that five IVIG products showed decreased viscosity at higher temperatures, which may lead to safer infusion practices. Additionally, GC Biopharma's varicella vaccine, BARYCELA, received marketing authorization in Vietnam after prior domestic approval and WHO Pre-Qualification.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
